Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to...
Saved in:
| Main Authors: | Mónica Bolufer, Jordi Soler, María Molina, Omar Taco, Anna Vila, Manuel Macía |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy
by: Anna Rudzińska, et al.
Published: (2024-11-01) -
Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01) -
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01) -
Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients
by: Marta Clos-Sansalvador, et al.
Published: (2024-11-01) -
Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)